Savient Pharmaceuticals Reports Second Quarter 2012 Financi... (plies Oxandrin ® (oxandrolone tabl...)

Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results

Date:8/8/2012

plies Oxandrin^® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

FORWARD-LOOKING STATEMENTSAll statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the safety and efficacy of KRYSTEXXA^®, the potential to expand the clinical utility of KRYSTEXXA, status of our KRYSTEXXA marketing efforts in the US and additional plans related thereto both in the US and ex-US, market demand and reimbursement for KRYSTEXXA, our view of the refractory chronic gout (RCG) market size in the US and ex-US, and our market expansion plans including our MAA filing before the EMA are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, developments that may arise in the litigation with Tang Capital; our ability to commercialize KRYSTEXXA; the risk that the market for KRYSTEXXA is smaller than we have anticipated;
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
2. UCF nanoparticle discovery opens door for pharmaceuticals
3. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
4. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
5. Optimer Pharmaceuticals Reports Second Quarter 2012 Financial Results
6. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
7. Global Biopharmaceuticals Market 2011-2015
8. Patient Advocate Foundation and Jazz Pharmaceuticals Announce Partnership for Narcolepsy CareLine
9. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
10. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
11. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference

Post Your Comments:

(Date:6/19/2013)... , June 19, 2013 Biotechnology industry pioneer ... with financial software provider BlackLine Systems and enterprise ... SAP ) for a webinar next week entitled "No ... from BlackLine and SAP to Help Keep Its Account Reconciliations ... http://photos.prnewswire.com/prnh/20061117/LAF027LOGO ) The webinar, geared at finance, ...

(Date:6/19/2013)... (PRWEB) June 18, 2013 A new ... materials, costs and other trends will highlight technical sessions ... California this fall. In its 33rd year, the three-day ... an exhibition of key suppliers, approximately 100 technical presentations ... SPIE, the international society for optics and photonics , ...

(Date:6/18/2013)... KONG, June 18, 2013 China Cord Blood ... "Company"), China,s leading provider of cord blood collection, laboratory ... services, today announced its preliminary unaudited financial results for ... 2013 ended March 31, 2013. Fourth ... the fourth quarter of fiscal 2013 increased by 33.3% ...

(Date:6/18/2013)... 18, 2013 The human skin is the ... an important human body part. Similar to the liver, or ... to function, repair and grow. Recent reports from the mankatofreepress.com ... is just as important as other life supporting organs. The ... in skin cell reproduction, increase the appearance of skin, and ...

[0] Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations [0] ‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin

... Halozyme Therapeutics, Inc. (Nasdaq: HALO ) ... the first patient received subcutaneous (SC) MabThera (rituximab), an ... Enhanze(™ technology (rHuPH20, recombinant human hyaluronidase). This ... Herceptin ® SC (trastuzumab), to enter a Phase ...

... Transgenomic, Inc. (OTC Bulletin Board: TBIO ) ... officer, will deliver the Company,s corporate presentation at Lippert/Heilshorn ... on Thursday, February 17, 2011 at 11:30 a.m. Eastern ... webcast with slide presentation at: www.transgenomic.com , or ...

... ROCKVILLE, Md., Feb. 15, 2011 Neuralstem, Inc. (NYSE ... business leader Stanley I. Westreich to its Board of ... comprised of a majority of independent directors. ... of Neuralstem,s Board of Directors and the Company,s Chief ...

Cached Biology Technology:Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) 2 Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) 3 Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) 4 Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 2 Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 3 Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board 2 Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board 3

Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board

(Date:6/19/2013)... of mammals and birds are threatened with extinction as a ... and colleagues from The Ohio State University in the US. ... exponential growth of the human population will continue to pose ... not appear to be a threshold above which population growth ... is published online in Springer,s journal, Human Ecology . ...

(Date:6/19/2013)... New York, NY, June 19, 2013 A ... Diabetes Research in Helmholtz Zentrum Mnchen, Germany, is ... autoantibodies and the risk of developing type 1 ... into possible preventions for the disease. The study, ... Progression to Diabetes in Children," was published today ...

(Date:6/19/2013)... offers further proof that the divergence of humans from ... was profoundly influenced by mutations to DNA sequences that ... The study, published June 9 in Nature Genetics ... of genes must play an important role in evolution ... in the proteins produced by genes. Indeed, human and ...

Breaking Biology News(10 mins):Are we pushing animals over the edge? 2 New data on islet autoantibodies in young children defines early type 1 diabetes development 2 New research backs theory that genetic 'switches' play big role in human evolution 2 New research backs theory that genetic 'switches' play big role in human evolution 3

[0] Are we pushing animals over the edge?[0] New data on islet autoantibodies in young children defines early type 1 diabetes development [0] New research backs theory that genetic 'switches' play big role in human evolution

... Bette Korber is part of an international team of ... trial of a mosaic HIV vaccine candidate. The vaccine ... causes AIDS by attempting to address one of the ... extensive genetic diversity. The team and its efforts ...

... UPTON, NY Scientists at the U.S. Department of ... have discovered a key difference in the way human ... unwanted proteins marked with a "kiss of death" ... critical difference, described in a paper published online October ...

... TAMPA, Fla., Sept. 22 Lockheed Martin (NYSE: ... new DNA analysis system that has potential to transform how ... in support of their missions. The prototype, called ... Biometric Consortium Conference special session on Rapid DNA. The ...

Cached Biology News:Consortium to design human trials of mosaic HIV vaccine 2 Key difference in how TB bacteria degrade doomed proteins 2 Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 2 Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 3

Consortium to design human trials of mosaic HIV vaccine Key difference in how TB bacteria degrade doomed proteins Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities

... no longer need to perform time consuming and ... Mutation Surveyor, any found variants of the sample ... indicated in our mutation electropherogram as a sharp ... bi-directional analysis mode is over 99%, with sensitivity ...

...

... 220-240 V, is used for biolistic particle ... device employs an adjustable helium pulse to ... microcarriers from the inner wall of a ... This system has a 2 square-centimeter target ...

Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...

Biology Products:

Mutation Surveyor from SoftGenetics, LLC.Finnigan LTQ FT from Thermo Scientific Helios Gene Gun System, 220-240 V from Bio-Rad Mouse Anti-Human YARS Monoclonal Antibody, Unconjugated, Clone 2F3 from Abnova Corporation